T47D Xenograft Model Service for Breast Cancer

The T47D xenograft model offers a highly characterized, hormone-dependent in vivo translational platform specifically optimized for validating novel endocrine therapies, selective estrogen receptor degraders (SERDs), and combination strategies against luminal breast cancer. Alfa Cytology delivers a comprehensive, end-to-end T47D xenograft model service, combining fully authenticated cell line assets with standardized exogenous hormone supplementation and molecular profiling to accelerate preclinical oncology drug discovery pipelines.

Overview of T47D Xenograft Model for Breast Cancer

The T47D cell line is a foundational and widely utilized human mammary carcinoma platform in preclinical oncology, serving as a classic reference matrix for studying luminal A subtype breast cancer biology and endocrine response profiles. Originally isolated from the pleural effusion of a 53-year-old Caucasian female patient presenting with an infiltrating ductal carcinoma, this model is molecularly classified by a distinct ER+ and PR+ status coupled with a lack of HER2 amplification. A defining genetic hallmark of T47D is its exceptionally high and stable expression of functional PR, which remains responsive to progesterone modulation despite harboring a specific missense mutation in the TP53 gene. This unique steroid receptor landscape makes the T47D model an indispensable test matrix for investigating target-mediated transcriptional regulation, deciphering cross-talk between estrogen and progesterone signaling axes, and profiling novel selective estrogen receptor modulators (SERMs) or aromatase inhibitors.

When established in vivo as a xenograft in immunodeficient mice, T47D cells develop into well-to-moderately differentiated epithelial solid tumors that faithfully recapitulate the histological features and low-grade proliferative index characteristic of clinical luminal malignancies. Crucially, because T47D is an exquisitely hormone-dependent platform, robust in vivo engraftment and sustained tumor growth kinetics strictly necessitate continuous exogenous estrogen supplementation, typically administered via slow-release subcutaneous 17β-estradiol pellets before inoculation.

Fig 1. Cell viability of T47D cells treated with tamoxifen and increased concentrations of AP-1 inhibitor SR11302, alone or in combination. (Padrão N, et al., 2026)

Cell Line Information: T47D

The T47D cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary hormone receptor-positive profile and estrogen-dependent growth kinetics upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the T47D Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, 17β-estradiol pellet implantation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for ER/PR status and PK/PD profiling. Leveraging our expertise in hormone-dependent luminal breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of T47D Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the T47D xenograft model:

• Cell Culture & Quality Control: T47D cells are cultivated in cell-bank-certified growth media supplemented with insulin under optimized atmospheric parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Hormone Pellet Implantation: Because T47D tumor take rates depend heavily on sustained hormone levels, immunocompromised mice are subcutaneously implanted with a validated, slow-release 17β-estradiol pellet under aseptic conditions prior to cell transfer.
• Precision Inoculation: A calibrated suspension of high-viability T47D cells is prepared and blended with a verified biological basement membrane matrix carrier to optimize spatial cell attachment. The mixture is precisely injected in vivo via orthotopic mammary fat pad or subcutaneous routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth kinetics are tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights, general welfare behavior, and pellet retention are routinely recorded.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. T47D Xenograft Model Construction Workflow

Case Study - T47D Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the T47D xenograft model was successfully utilized to evaluate the therapeutic efficacy and target engagement of a novel next-generation oral SERD compound as a monotherapy and in combination with a CDK4/6 inhibitor. Under optimized estrogen-supplemented modeling conditions and standardized matrix-assisted inoculation protocols, our technical team achieved highly reproducible tumor engraftment and uniform growth kinetics across all cohorts, enabling an unobstructed and definitive assessment of endocrine sensitivity.

Our Advantages

Choosing the right partner for your hormone-receptor-positive luminal breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks and confirmed ER+/PR+ expression profiles.
• Technical Consistency: Standardized 17β-estradiol pellet supplementation and optimized inoculation protocols ensuring uniform tumor kinetics and minimized variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, steroid receptor density profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research and animal welfare standards.

Contact Us

Are you looking to advance your therapeutic pipeline against hormone-receptor-positive luminal breast cancer or evaluate novel endocrine strategies using the robust T47D xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.